Delhi NCR
- biomarkers
- 1,168 reports mapped to Delhi NCR via pincode
- survey
- 1,204 respondents resident in Delhi NCR
- The pollution link is mechanistic, not metaphorical
- Delhi's liver strain is overwhelmingly a male strain
- The damage shows up early and recedes — the opposite of the glucose curve
- Delhi's apparent glucose improvement is a sample correction, not a recovery
- The rest of the Delhi biomarker panel
- What the Delhi workforce reports about how it lives
Key takeaways
- 34.4% of Delhi NCR workers tested show liver dysfunction — roughly 1.6× the next-worst metro (Hyderabad 21.7%, Mumbai 20.2%) and an almost exact replication of WHI 2025's 34.8%. On every other biomarker Delhi is unremarkable; on liver it is an outlier.
- The liver gap is a male gap. 47.5% of Delhi men tested are in the dysfunction band against 17.0% of women — a 2.8× spread, the widest single-city gender split on any biomarker in the 2026 dataset.
- Delhi's liver burden peaks in the 30s and recedes after 40 — the inverse of the glucose curve. Delhi men in their 30s sit at 56.3% liver dysfunction.
- Delhi's average SGPT is 41.2 U/L, against 27–31 U/L in the other four metros, and GGT elevation runs at 11.0% against 5–7% elsewhere — the enzyme profile of a population under sustained hepatic load.
- Delhi's apparent glucose improvement — 43.1% in 2025 to 32.7% in 2026 — is a measurement correction, not a real change. The 2025 reading came from 130 reports; the 2026 reading from 689.
Of 765 Delhi NCR liver panels Loop ran in the latest 12-month window, 34.4% sit in the dysfunction band — SGPT, SGOT, or GGT above its clinical ceiling. That 34.4% is the city number behind the report's Liver Health page. The next-worst metro, Hyderabad, sits at 21.7%; Mumbai, Pune, and Bengaluru cluster between 18% and 20%. Delhi's liver dysfunction rate is roughly 1.6 times the runner-up and nearly double the metro floor. The WHI 2025 edition put the figure at 34.8%. Across two editions and very different sample sizes, the Delhi liver finding is the most stable single-city signal in the report — and it sits in the city with India's worst measured air, where PM2.5 routinely runs several times the WHO guideline through the winter inversion months (CSE India, 2025).
| Metro | Any liver dysfunction | SGPT-only | GGT >60 | Avg SGPT (U/L) | n |
|---|---|---|---|---|---|
| Delhi NCR | 34.4% | 30.6% | 11.0% | 41.2 | 765 |
| Hyderabad | 21.7% | 18.9% | 5.7% | 30.6 | 470 |
| Mumbai | 20.2% | 15.9% | 7.4% | 29.1 | 1,090 |
| Pune | 18.7% | 16.1% | 5.4% | 27.3 | 2,480 |
| Bengaluru | 18.4% | 15.6% | 6.2% | 27.1 | 1,913 |
Delhi's liver dysfunction is 1.6× the next-worst metro
Share with SGPT, SGOT, or GGT above its clinical ceiling, ranked — average SGPT beneath each city
Delhi leads on both prevalence and central tendency: its average SGPT of 41.2 U/L is itself above the 40 U/L dysfunction threshold. The whole distribution has shifted, not just the tail.
The average-SGPT column is the read worth pausing on. Prevalence rates can be pushed up by a heavy tail — a small number of very abnormal results. Delhi's average SGPT of 41.2 U/L is itself above the 40 U/L dysfunction threshold, which means the centre of the Delhi distribution sits where the other metros' tails begin. This is not a few sick livers dragging up a rate. It is a whole population reading high.
The pollution link is mechanistic, not metaphorical#
Delhi's liver outlier status survives the obvious confounders. Income, diet, and healthcare access are broadly comparable across the five metros Loop samples; Delhi's professionals are not poorer, less educated, or less screened than Bengaluru's. The variable Delhi does not share with the others is its air. Peer-reviewed work over the last decade has moved the PM2.5–liver link from association to mechanism.
The liver is not the only organ registering the air. The same research note records that 79.8% of a 4,000-person Delhi-NCR survey were either planning to relocate or had already left, with half citing personal health as the main reason (Smytten PulseAI, 2024–25). The biomarker and the behaviour point the same direction: Delhi's workforce is carrying a measurable hepatic cost, and a meaningful share of it is voting with its feet.
Delhi's liver strain is overwhelmingly a male strain#
The single-city headline hides a split sharp enough to change what an employer should do about it.
| Group | Any liver dysfunction | SGPT-only | n |
|---|---|---|---|
| Men | 47.5% | 43.1% | 436 |
| Women | 17.0% | 14.0% | 329 |
Delhi's liver strain is overwhelmingly a male strain
Any liver dysfunction by gender, from a common zero
A 30.5-point gap (47.5% vs 17.0%) — the widest single-city gender split on any biomarker in the 2026 dataset. SGPT-only rates run 43.1% for men, 14.0% for women.
Nearly half of Delhi men tested are in the liver dysfunction band, against fewer than one in five women. A 2.8× gap is wide for any biomarker; on a gender cut within a single city it is the widest split anywhere in the 2026 dataset. The contributing factors stack. Visceral fat — the metabolically active abdominal fat that drives fatty liver — accumulates more readily in men. Alcohol, which Delhi men report at higher rates than women, runs its clearance through the liver and shows up specifically in GGT. And the male body composition that protects against anemia (Delhi female anemia is 41.4%, male 11.9%) offers no protection here; it works the other way.
The damage shows up early and recedes — the opposite of the glucose curve#
Most biomarkers worsen monotonically with age. Glucose dysfunction in Delhi follows that rule precisely — 9.6% in the 20s, 27.8% in the 30s, 49.3% in the 40s, climbing past 70% by 60. The liver does not.
| Age band | Liver dysfunction (any) | Glucose dysfunction | n (liver) |
|---|---|---|---|
| 20–29 | 35.9% | 9.6% | 248 |
| 30–39 | 42.4% | 27.8% | 271 |
| 40–49 | 31.8% | 49.3% | 85 |
| 50–59 | 21.5% | 64.6% | 93 |
| 60+ | 18.6% | 73.8% | 59 |
One curve climbs, the other peaks young and falls
Liver dysfunction vs glucose dysfunction by age band, Delhi NCR
The curves cross in the 40s (31.8% liver vs 49.3% glucose) — the preventive window for Delhi's liver problem opens earlier than for its glucose problem. Liver band n = 248 / 271 / 85 / 93 / 59; the 40+ cells are small and directional, the 20s–30s cells are robust.
Liver dysfunction in Delhi peaks in the 30s at 42.4% and then declines — Delhi men in their 30s read 56.3% in the dysfunction band. This is a younger signal than the chronic-disease story usually allows. Two readings fit the shape. The first is exposure-dose: the heaviest liver enzyme leakage tracks the years of densest alcohol use, fastest weight gain, and longest commute-hours through the worst air, which for this workforce is the late 20s and 30s. The second is survivorship — the older bands are thinner and may under-represent the men whose livers carried the highest load. Either way, the preventive window for Delhi's liver problem opens earlier than for its glucose problem, not later.
Delhi's apparent glucose improvement is a sample correction, not a recovery#
WHI 2025 ranked Delhi the worst-glucose metro at 43.1%. WHI 2026 places it at 32.7% — near the middle of the pack. The temptation is to read a ten-point drop as a win. It is not one.
| Metric | WHI 2025 | WHI 2026 | Δ pp |
|---|---|---|---|
| Glucose dysfunction (HbA1c ≥5.7%) | 43.1% | 32.7% | −10.4 |
| Sample (HbA1c) | 130 | 689 | 5.3× |
| Diabetic range (HbA1c ≥6.5%) | 16.2% | 12.9% | −3.3 |
A sample correction, not a recovery
Glucose dysfunction (HbA1c ≥5.7%), WHI 2025 vs WHI 2026
The 2025 reading rode on 130 HbA1c reports — too thin to be stable. Treat the −10.4 pp move as a measurement correction revealing the actual rate, not a real improvement: the 2026 number is the baseline. Diabetic-range share moved 16.2% → 12.9% on the same correction.
The same denominator lesson runs through the report's Blood Sugar page, where Pune's mirror-image jump makes the case at length. The liver finding carries no such caveat, which is part of why it anchors this page. Delhi's liver dysfunction was 34.8% on the 2025 sample and 34.4% on a sample several times larger. When the n grew, the glucose number moved and the liver number did not. The signal that survives the better measurement is the one to build on.
The rest of the Delhi biomarker panel#
Outside liver, Delhi sits inside the metro range on most markers — which is itself the finding. The capital is not uniformly unhealthy; it is specifically liver-strained.
| Biomarker | Delhi NCR rate | Threshold | n |
|---|---|---|---|
| Vitamin D insufficient | 72.9% | <30 ng/mL | 702 |
| B12 low | 67.7% | <300 pg/mL | 657 |
| HDL low (gender-aware) | 56.6% | F<50 / M<40 | 691 |
| Female anemia | 41.4% | Hb <12 | 435 |
| HDL critically low | 39.1% | <40 mg/dL | 691 |
| Glucose dysfunction | 32.7% | HbA1c ≥5.7% | 689 |
| Male anemia | 11.9% | Hb <13 | 497 |
Outside the liver, Delhi is unremarkable
Delhi NCR biomarker rates, ranked, with each clinical threshold
Every marker here sits inside the five-metro range — high vitamin D and B12 deficits are ordinary urban deficits, not Delhi outliers. The one outlier, liver, is charted at the top of the page.
Vitamin D insufficiency at 72.9% and B12 deficiency at 67.7% are high, but they are high everywhere in urban India — Bengaluru reads worse on B12. The HDL and anemia figures sit mid-pack. The 2025 edition framed Delhi's vitamin D and B12 as relative strengths against other metros; on the larger 2026 sample they read as ordinary urban deficits, neither a strength nor an outlier. The story that separates Delhi from the other four metros is liver, and only liver.
What the Delhi workforce reports about how it lives#
The survey side, 1,204 Delhi NCR respondents, corroborates the biomarker picture without contradicting it.
| Behaviour | Delhi NCR | n |
|---|---|---|
| Any workday caffeine | 82.2% | 998 |
| Any alcohol consumption | 43.6% | 1,002 |
| Took no preventive action in last year | 40.5% | 975 |
| Zero 30-minute exercise days | 31.5% | 1,038 |
| Sleep under 6 hours | 29.2% | 1,049 |
| Current nicotine use | 21.7% | 999 |
Delhi runs ahead of the national line on the loads the liver processes
Survey behaviour signals — tick marks the all-India survey rate
All-India markers from the WHI 2026 lifestyle pages: caffeine 76.6% · alcohol 37.3% · no preventive action 42.3% · zero exercise 30.9% · sleep 30.7% · nicotine 17.2%. Alcohol and nicotine both run ahead of the national rate — and both are higher in the male majority of this sample, the same group carrying the liver damage. Row n = 998 / 1,002 / 975 / 1,038 / 1,049 / 999.
Two numbers connect to the liver finding. Alcohol consumption at 43.6% and nicotine use at 21.7% are both substance loads the liver processes, and both are higher in the male majority of this sample (72% of Delhi survey respondents are men) — the same group carrying the liver damage. The 40.5% who took no preventive action in the past year is the operational gap: in a city where the liver signal is this loud, two in five workers did nothing about their health at all.
Delhi's stress and sleep readings barely moved from 2025 — high stress held near 41.5%, short sleep at 29.2%. The environmental and occupational pressures the 2025 page described are still present; they have neither worsened nor eased. What the better-measured 2026 data adds is precision about where those pressures land hardest.
References
- 1Anjana, R.M., Unnikrishnan, R., Anjana, R. et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study. The Lancet Diabetes & Endocrinology 11, 474–489 (2023). https://doi.org/10.1016/S2213-8587(23)00119-5
- 2Guo, B., Guo, Y., Nima, Q. et al. Exposure to air pollution is associated with an increased risk of metabolic dysfunction-associated fatty liver disease. Journal of Hepatology 76, 518–525 (2022). https://doi.org/10.1016/j.jhep.2021.10.016
- 3Li, W., Dorans, K.S., Wilker, E.H. et al. Residential proximity to major roadways, fine particulate matter, and hepatic steatosis. American Journal of Epidemiology 186, 857–865 (2017). https://doi.org/10.1093/aje/kwx127
- 4Duseja, A., Singh, S.P., De, A. et al. Indian National Association for Study of the Liver (INASL) guidance on metabolic dysfunction-associated fatty liver disease. Journal of Clinical and Experimental Hepatology 13, 273–302 (2023). https://doi.org/10.1016/j.jceh.2022.11.014